Viatris Retains Interest In OTC As It Spies Switch Opportunities

Viatris has penned a deal worth $2bn to offload “substantially all” of its OTC assets but has decided to retain select consumer health products and Rx-to-OTC switch candidates, including erectile dysfunction treatment Viagra.

• Source: Shutterstock

Viatris is bucking the trend of major pharma players exiting the consumer health market by partially reversing its decision to divest its OTC business.

The Canonsburg, PA-based firm described OTC as “non core” in November 2022 as it put the business up for sale...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health